The DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology annual meeting, established trastuzumab deruxtecan (T-DXd; Enhertu) plus pertuzumab (Perjeta) as a new first-line treatment option for patients with HER2-positive metastatic breast cancer, while raising new questions about patient selection and treatment duration.
MedPage Today brought together three expert leaders in the field: Moderator Hope S. Rugo, MD, of the City of Hope Comprehensive Cancer Center in Duarte, California, is joined by William J. Gradishar, MD, of Northwestern University Feinberg School of Medicine in Chicago, and Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute in Boston, for a virtual roundtable discussion. In this fourth and final exclusive episode, the panel discusses which patients are most likely to benefit from the DESTINY-Breast09 regimen, whether traditional first-line approaches still have a role, and how long T-DXd should be continued in clinical practice.
Click here to watch the other videos from this series.
Following is a transcript of their remarks:
Rugo: DB-09, do you think we should always start with T-DXd now with metastatic HER2-positive disease where you didn't just give it?
